Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 5/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KYNU | Q16719 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199790 | 1.00 | ITGB3 (0.53) | ITGB3ITGA2BPPARAATMCTSS | |
| SCHEMBL7513292 | 1.00 | ITGB3 (0.53) | ITGB3ITGA2BPPARAATMCTSS | |
| SCHEMBL1199068 | 0.92 | KYNU (0.54) | ITGB3ITGA2BATMCTSSCTSL | |
| SCHEMBL1199066 | 0.92 | KYNU (0.54) | ITGB3ITGA2BATMCTSSCTSL | |
| SCHEMBL15936883 | 0.92 | KYNU (0.54) | ITGB3ITGA2BATMCTSSCTSL | |
| SCHEMBL30801699 | 0.91 | CTSL (0.49) | ITGB3ITGA2BATMCTSSCTSL | |
| SCHEMBL17357790 | 0.89 | CTSS (0.50) | ITGB3ITGA2BATMCTSSCTSL | |
| SCHEMBL13057155 | 0.89 | CTSK (0.49) | ITGB3ITGA2BATMCTSSCTSL | |
| SCHEMBL2863999 | 0.89 | CTSS (0.50) | ITGB3ITGA2BATMCTSSCTSL | |
| SCHEMBL20556338 | 0.88 | ITGB3 (0.53) | ITGB3ITGA2BPPARAATMCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3576743-B1 | 5-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-5-AZASPIRO[2 5]OCTANE-8-CARBOXYLIC ACID DERIVATIVES AS JAK KINASE INHIBITORS | LEO PHARMA AS (DK) | 2023-01-18 | — | — | EP | disclosed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-10799507-B2 | 5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors | LEO PHARMA A/S (DK) | 2020-10-13 | — | — | US | disclosed |
| US-7888351-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-02-15 | — | — | US | disclosed |
| US-20110034462-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2011-02-10 | — | — | US | disclosed |
| US-20090281069-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-11-12 | — | — | US | disclosed |
| EP-2007723-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007115821-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | ITGB3 3622/4885ITGA2B 3396/4885PPARA 1332/4885 |
| US-10799507-B2 | 5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors | JAK3, JAK1, JAK2 | ITGB3 1437/4885ITGA2B 4169/4885PPARA 1081/4885 |
| US-20090281069-A1 | ORGANIC COMPOUNDS | OTC, OAT, SLCO2B1 | ITGB3 2562/4885ITGA2B 3088/4885PPARA 880/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | ITGB3 3622/4885ITGA2B 3396/4885PPARA 1332/4885 |
| US-20110034462-A1 | ORGANIC COMPOUNDS | OTC, OAT, SLCO2B1 | ITGB3 2562/4885ITGA2B 3088/4885PPARA 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.